A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer

BACKGROUND: Antiangiogenic agents provides an optional treatment strategy for patients with metastatic breast cancer. The present study was conducted to evaluate the efficacy and safety of anlotinib as third-line or above therapy for patients with HER-2 negative metastatic breast cancer. METHODS: Pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Yingbo, Luo, Zhifen, Yu, Yang, He, Yaning, Liu, Chaojun, Chen, Qi, Zhu, Fangyuan, Nie, Bing, Liu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366600/
https://www.ncbi.nlm.nih.gov/pubmed/35965587
http://dx.doi.org/10.3389/fonc.2022.939343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366600/
https://www.ncbi.nlm.nih.gov/pubmed/35965587
http://dx.doi.org/10.3389/fonc.2022.939343

Ejemplares similares